Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study

PURPOSE: The performance of alectinib and crizotinib in untreated anaplastic lymphoma kinase (ALK)-positive patients with non-small-cell lung cancer (NSCLC) and symptomatic and synchronic brain metastases is largely unknown. This retrospective study assessed the effectiveness of alectinib and crizot...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Qiang, Li, Peng, Wang, Peng, Zhang, Zhen, Liu, Qun, Sun, Zengfeng, Li, Wenliang, Ma, Li, Wang, Xiaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722687/
https://www.ncbi.nlm.nih.gov/pubmed/35002258
http://dx.doi.org/10.2147/OTT.S345439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722687/
https://www.ncbi.nlm.nih.gov/pubmed/35002258
http://dx.doi.org/10.2147/OTT.S345439

Ejemplares similares